docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2022-21-2-23-29docru-54Research ArticleГАСТРОЭНТЕРОЛОГИЯGASTROENTEROLOGYМеханизмы и клиническое значение печеночного фиброгенеза при перегрузке железомMechanisms and Clinical Significance of Hepatic Fibrogenesis in Iron Overloahttps://orcid.org/0000-0001-9809-8015ГарбузенкоД. В.GarbuzenkoD. V.

Гарбузенко Дмитрий Викторович — профессор кафедры факультетской хирургии, д. м. н., профессор454092, г. Челябинск

garb@inbox.ruФГБОУ ВО «Южно-Уральский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияSouth Ural State Medical University of the Ministry of Health of the Russian FederationRussian Federation202214022025212ТЕРАПИЯ2329Copyright © Гарбузенко Д.В., 20252025Гарбузенко Д.В.Garbuzenko D.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/54Цель обзора

Цель обзора: описать механизмы и клиническое значение печеночного фиброгенеза при перегрузке железом у пациентов с наследственным гемохроматозом и хроническими заболеваниями печени.

Основные положения

Основные положения. Перегрузка железом токсична и может способствовать печеночному фиброгенезу. Развитие фиброза печени является неблагоприятным событием естественного течения как наследственного гемохроматоза, так и хронических заболеваний печени, поскольку может привести к формированию цирроза печени и гепатоцеллюлярной карциномы.

Заключение

Заключение. Имеющие перегрузку железом больные должны быть стратифицированы по группам риска с целью ранней диагностики фиброза печени и определения оптимальной лечебной тактики

Objective of the Review

Objective of the Review: To describe the mechanisms and clinical significance of hepatic fibrogenesis in iron overload in patients with hereditary hemochromatosis and chronic hepatic conditions.

Key Points

Key Points. Iron overload is toxic and can facilitate hepatic fibrogenesis. Hepatic fibrogenesis is an unfavourable natural event both of hereditary hemochromatosis and chronic hepatic conditions, since it can cause hepatic cirrhosis and hepatocellular carcinoma.

Conclusion

Conclusion. Patients with iron overload should be stratified into at-risk groups for early diagnosis of hepatic fibrosis and optimal management

перегрузка железомпеченочный фиброгенезнаследственный гемохроматозхронические заболевания печенидиагностикалечениеiron overloadhepatic fibrogenesishereditary hemochromatosischronic hepatic conditionsdiagnosismanagementReferencesГарбузенко Д.В. Молекулярные стимулы фиброгенной активации звездчатых клеток печени. Патологическая физиология и экспериментальная терапия. 2022; 66(1): 112–9. [Garbuzenko D.V. Molecular stimuli of fibrogenic activation in hepatic stellate cells. Pathological Physiology and Experimental Therapy. 2022; 66(1): 112–9. (in Russian)]. DOI: 10.25557/0031-2991.2022.01.112-119Гарбузенко Д.В. Молекулярные стимулы фиброгенной активации звездчатых клеток печени. Патологическая физиология и экспериментальная терапия. 2022; 66(1): 112–9. [Garbuzenko D.V. Molecular stimuli of fibrogenic activation in hepatic stellate cells. Pathological Physiology and Experimental Therapy. 2022; 66(1): 112–9. (in Russian)]. DOI: 10.25557/0031-2991.2022.01.112-119Mehta K.J., Coombes J.D., Briones-Orta M. et al. Iron enhances hepatic fibrogenesis and activates transforming growth factor-β signaling in murine hepatic stellate cells. Am. J. Med. Sci. 2018; 355(2): 183–90. DOI: 10.1016/j.amjms.2017.08.012Mehta K.J., Coombes J.D., Briones-Orta M. et al. Iron enhances hepatic fibrogenesis and activates transforming growth factor-β signaling in murine hepatic stellate cells. Am. J. Med. Sci. 2018; 355(2): 183–90. DOI: 10.1016/j.amjms.2017.08.012Mehta K.J., Farnaud S.J., Sharp P.A. Iron and liver fibrosis: mechanistic and clinical aspects. World J. Gastroenterol. 2019; 25(5): 521–38. DOI: 10.3748/wjg.v25.i5.521Mehta K.J., Farnaud S.J., Sharp P.A. Iron and liver fibrosis: mechanistic and clinical aspects. World J. Gastroenterol. 2019; 25(5): 521–38. DOI: 10.3748/wjg.v25.i5.521Bloomer S.A., Brown K.E. Iron-induced liver injury: a critical reappraisal. Int. J. Mol. Sci. 2019; 20(9): 2132. DOI: 10.3390/ijms20092132Bloomer S.A., Brown K.E. Iron-induced liver injury: a critical reappraisal. Int. J. Mol. Sci. 2019; 20(9): 2132. DOI: 10.3390/ijms20092132Parrow N.L., Fleming R.E. Bone morphogenetic proteins as regulators of iron metabolism. Annu. Rev. Nutr. 2014; 34: 77–94. DOI: 10.1146/annurev-nutr-071813-105646Parrow N.L., Fleming R.E. Bone morphogenetic proteins as regulators of iron metabolism. Annu. Rev. Nutr. 2014; 34: 77–94. DOI: 10.1146/annurev-nutr-071813-105646Ruddell R.G., Hoang-Le D., Barwood J.M. et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology. 2009; 49(3): 887–900. DOI: 10.1002/hep.22716Ruddell R.G., Hoang-Le D., Barwood J.M. et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology. 2009; 49(3): 887–900. DOI: 10.1002/hep.22716Bridle K.R., Crawford D.H., Ramm G.A. Identification and characterization of the hepatic stellate cell transferrin receptor. Am. J. Pathol. 2003; 162(5): 1661–7. DOI: 10.1016/S0002-9440(10)64300-3Bridle K.R., Crawford D.H., Ramm G.A. Identification and characterization of the hepatic stellate cell transferrin receptor. Am. J. Pathol. 2003; 162(5): 1661–7. DOI: 10.1016/S0002-9440(10)64300-3Mandala A., Chen W.J., Armstrong A. et al. PPARα agonist fenofibrate attenuates iron-induced liver injury in mice by modulating the Sirt3 and β-catenin signaling. Am. J. Physiol. Gastrointest. Liver Physiol. 2021; 321(4): 262–9. DOI: 10.1152/ajpgi.00129.2021Mandala A., Chen W.J., Armstrong A. et al. PPARα agonist fenofibrate attenuates iron-induced liver injury in mice by modulating the Sirt3 and β-catenin signaling. Am. J. Physiol. Gastrointest. Liver Physiol. 2021; 321(4): 262–9. DOI: 10.1152/ajpgi.00129.2021Brissot P., Pietrangelo A., Adams P.C. et al. Haemochromatosis. Nat. Rev. Dis. Primers. 2018; 4: 18016. DOI: 10.1038/nrdp.2018.16Brissot P., Pietrangelo A., Adams P.C. et al. Haemochromatosis. Nat. Rev. Dis. Primers. 2018; 4: 18016. DOI: 10.1038/nrdp.2018.16Brissot P., Loréal O. Hemochromatoses. J. Hepatol. 2021; 75(3): 723–4. DOI: 10.1016/j.jhep.2021.04.001Brissot P., Loréal O. Hemochromatoses. J. Hepatol. 2021; 75(3): 723–4. DOI: 10.1016/j.jhep.2021.04.001Pietrangelo A. Iron and the liver. Liver Int. 2016; 36(suppl.1): 116– 23. DOI: 10.1111/liv.13020Pietrangelo A. Iron and the liver. Liver Int. 2016; 36(suppl.1): 116– 23. DOI: 10.1111/liv.13020Barton J.C., McLaren C.E., Chen W.P. et al. Cirrhosis in hemochromatosis: independent risk factors in 368 HFE p.C282Y homozygotes. Ann. Hepatol. 2018; 17(5): 871–9. DOI: 10.5604/01.3001.0012.3169Barton J.C., McLaren C.E., Chen W.P. et al. Cirrhosis in hemochromatosis: independent risk factors in 368 HFE p.C282Y homozygotes. Ann. Hepatol. 2018; 17(5): 871–9. DOI: 10.5604/01.3001.0012.3169Buch S., Sharma A., Ryan E. et al. Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis. Aliment. Pharmacol. Ther. 2021; 53(7): 830– 43. DOI: 10.1111/apt.16252Buch S., Sharma A., Ryan E. et al. Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis. Aliment. Pharmacol. Ther. 2021; 53(7): 830– 43. DOI: 10.1111/apt.16252Osterreicher C.H., Datz C., Stickel F. et al. TGF-beta1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. Cytokine. 2005; 31(2): 142–8. DOI: 10.1016/j.cyto.2005.03.005Osterreicher C.H., Datz C., Stickel F. et al. TGF-beta1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. Cytokine. 2005; 31(2): 142–8. DOI: 10.1016/j.cyto.2005.03.005Stickel F., Osterreicher C.H., Datz C. et al. Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch. Intern. Med. 2005; 165(16): 1835–40. DOI: 10.1001/archinte.165.16.1835Stickel F., Osterreicher C.H., Datz C. et al. Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch. Intern. Med. 2005; 165(16): 1835–40. DOI: 10.1001/archinte.165.16.1835Osterreicher C.H., Datz C., Stickel F. et al. Association of myeloperoxidase promotor polymorphism with cirrhosis in patients with hereditary hemochromatosis. J. Hepatol. 2005; 42(6): 914–9. DOI: 10.1016/j.jhep.2005.01.023Osterreicher C.H., Datz C., Stickel F. et al. Association of myeloperoxidase promotor polymorphism with cirrhosis in patients with hereditary hemochromatosis. J. Hepatol. 2005; 42(6): 914–9. DOI: 10.1016/j.jhep.2005.01.023Wood M.J., Gadd V.L., Powell L.W. et al. Ductular reaction in hereditary hemochromatosis: the link between hepatocyte senescence and fibrosis progression. Hepatology. 2014; 59(3): 848–57. DOI: 10.1002/hep.26706Wood M.J., Gadd V.L., Powell L.W. et al. Ductular reaction in hereditary hemochromatosis: the link between hepatocyte senescence and fibrosis progression. Hepatology. 2014; 59(3): 848–57. DOI: 10.1002/hep.26706Kowdley K.V., Brown K.E., Ahn J. et al. ACG Clinical Guideline: hereditary hemochromatosis. Am. J. Gastroenterol. 2019; 114(8): 1202–18. DOI: 10.14309/ajg.0000000000000315Kowdley K.V., Brown K.E., Ahn J. et al. ACG Clinical Guideline: hereditary hemochromatosis. Am. J. Gastroenterol. 2019; 114(8): 1202–18. DOI: 10.14309/ajg.0000000000000315Philippe M.A., Ruddell R.G., Ramm G.A. Role of iron in hepatic fibrosis: one piece in the puzzle. World J. Gastroenterol. 2007; 13(35): 4746–54. DOI: 10.3748/wjg.v13.i35.4746Philippe M.A., Ruddell R.G., Ramm G.A. Role of iron in hepatic fibrosis: one piece in the puzzle. World J. Gastroenterol. 2007; 13(35): 4746–54. DOI: 10.3748/wjg.v13.i35.4746Kisseleva T., Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat. Rev. Gastroenterol. Hepatol. 2021; 18(3): 151–66. DOI: 10.1038/s41575-020-00372-7Kisseleva T., Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat. Rev. Gastroenterol. Hepatol. 2021; 18(3): 151–66. DOI: 10.1038/s41575-020-00372-7Rigamonti C., Andorno S., Maduli E. et al. Iron, hepatic stellate cells and fibrosis in chronic hepatitis C. Eur. J. Clin. Invest. 2002; 32(suppl.1): 28–35. DOI: 10.1046/j.1365-2362.2002.0320s1028.xRigamonti C., Andorno S., Maduli E. et al. Iron, hepatic stellate cells and fibrosis in chronic hepatitis C. Eur. J. Clin. Invest. 2002; 32(suppl.1): 28–35. DOI: 10.1046/j.1365-2362.2002.0320s1028.xSikorska K. The iron homeostasis network and hepatitis C virus — a new challenge in the era of directly acting antivirals. Virulence. 2016; 7(6): 620–2. DOI: 10.1080/21505594.2016.1191739Sikorska K. The iron homeostasis network and hepatitis C virus — a new challenge in the era of directly acting antivirals. Virulence. 2016; 7(6): 620–2. DOI: 10.1080/21505594.2016.1191739Gao Y.H., Wang J.Y., Liu P.Y. et al. Iron metabolism disorders in patients with hepatitis B-related liver diseases. World J. Clin. Cases. 2018; 6(13): 600–10. DOI: 10.12998/wjcc.v6.i13.600Gao Y.H., Wang J.Y., Liu P.Y. et al. Iron metabolism disorders in patients with hepatitis B-related liver diseases. World J. Clin. Cases. 2018; 6(13): 600–10. DOI: 10.12998/wjcc.v6.i13.600Georgopoulou U., Dimitriadis A., Foka P. et al. Hepcidin and the iron enigma in HCV infection. Virulence. 2014; 5(4): 465–76. DOI: 10.4161/viru.28508Georgopoulou U., Dimitriadis A., Foka P. et al. Hepcidin and the iron enigma in HCV infection. Virulence. 2014; 5(4): 465–76. DOI: 10.4161/viru.28508Shan Y., Lambrecht R.W., Bonkovsky H.L. Association of hepatitis C virus infection with serum iron status: analysis of data from the third National Health and Nutrition Examination Survey. Clin. Infect. Dis. 2005; 40(6): 834–41. DOI: 10.1086/428062Shan Y., Lambrecht R.W., Bonkovsky H.L. Association of hepatitis C virus infection with serum iron status: analysis of data from the third National Health and Nutrition Examination Survey. Clin. Infect. Dis. 2005; 40(6): 834–41. DOI: 10.1086/428062Sikorska K., Romanowski T., Stalke P. et al. Association of hepcidin mRNA expression with hepatocyte iron accumulation and effects of antiviral therapy in chronic hepatitis C infection. Hepat. Mon. 2014; 14(11): e21184. DOI: 10.5812/hepatmon.21184Sikorska K., Romanowski T., Stalke P. et al. Association of hepcidin mRNA expression with hepatocyte iron accumulation and effects of antiviral therapy in chronic hepatitis C infection. Hepat. Mon. 2014; 14(11): e21184. DOI: 10.5812/hepatmon.21184Sebastiani G., Tempesta D., Alberti A. Hepatic iron overload is common in chronic hepatitis B and is more severe in patients coinfected with hepatitis D virus. J. Viral. Hepat. 2012; 19(2): e170–6. DOI: 10.1111/j.1365-2893.2011.01508.xSebastiani G., Tempesta D., Alberti A. Hepatic iron overload is common in chronic hepatitis B and is more severe in patients coinfected with hepatitis D virus. J. Viral. Hepat. 2012; 19(2): e170–6. DOI: 10.1111/j.1365-2893.2011.01508.xPark S.O., Kumar M., Gupta S. TGF-β and iron differently alter HBV replication in human hepatocytes through TGF-β/BMP signaling and cellular microRNA expression. PLoS One. 2012; 7(6): e39276. DOI: 10.1371/journal.pone.0039276Park S.O., Kumar M., Gupta S. TGF-β and iron differently alter HBV replication in human hepatocytes through TGF-β/BMP signaling and cellular microRNA expression. PLoS One. 2012; 7(6): e39276. DOI: 10.1371/journal.pone.0039276Fujita N., Sugimoto R., Urawa N. et al. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. J. Gastroenterol. Hepatol. 2007; 22(11): 1886–93. DOI: 10.1111/j.1440-1746.2006.04759.xFujita N., Sugimoto R., Urawa N. et al. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. J. Gastroenterol. Hepatol. 2007; 22(11): 1886–93. DOI: 10.1111/j.1440-1746.2006.04759.xMummadi R., Kasturi K., Sood G. Iron depletion and response to interferon in chronic hepatitis C: a meta-analysis [abstract]. Hepatology. 2007; 46: 365A.Mummadi R., Kasturi K., Sood G. Iron depletion and response to interferon in chronic hepatitis C: a meta-analysis [abstract]. Hepatology. 2007; 46: 365A.Franchini M., Targher G., Capra F. et al. The effect of iron depletion on chronic hepatitis C virus infection. Hepatol. Int. 2008; 2(3): 335–40. DOI: 10.1007/s12072-008-9076-zFranchini M., Targher G., Capra F. et al. The effect of iron depletion on chronic hepatitis C virus infection. Hepatol. Int. 2008; 2(3): 335–40. DOI: 10.1007/s12072-008-9076-zCosta Matos L., Batista P., Monteiro N. et al. Iron stores assessment in alcoholic liver disease. Scand. J. Gastroenterol. 2013; 48(6): 712–8. DOI: 10.3109/00365521.2013.781217Costa Matos L., Batista P., Monteiro N. et al. Iron stores assessment in alcoholic liver disease. Scand. J. Gastroenterol. 2013; 48(6): 712–8. DOI: 10.3109/00365521.2013.781217Milic S., Mikolasevic I., Orlic L. et al. The role of iron and iron overload in chronic liver disease. Med. Sci. Monit. 2016; 22: 2144–51. DOI: 10.12659/MSM.896494Milic S., Mikolasevic I., Orlic L. et al. The role of iron and iron overload in chronic liver disease. Med. Sci. Monit. 2016; 22: 2144–51. DOI: 10.12659/MSM.896494Ioannou G.N., Weiss N.S., Kowdley K.V. Relationship between transferrin-iron saturation, alcohol consumption, and the incidence of cirrhosis and liver cancer. Clin. Gastroenterol. Hepatol. 2007; 5(5): 624–9. DOI: 10.1016/j.cgh.2007.01.008Ioannou G.N., Weiss N.S., Kowdley K.V. Relationship between transferrin-iron saturation, alcohol consumption, and the incidence of cirrhosis and liver cancer. Clin. Gastroenterol. Hepatol. 2007; 5(5): 624–9. DOI: 10.1016/j.cgh.2007.01.008Costa-Matos L., Batista P., Monteiro N. et al. Liver hepcidin mRNA expression is inappropriately low in alcoholic patients compared with healthy controls. Eur. J. Gastroenterol. Hepatol. 2012; 24(10): 1158–65. DOI: 10.1097/MEG.0b013e328355cfd0Costa-Matos L., Batista P., Monteiro N. et al. Liver hepcidin mRNA expression is inappropriately low in alcoholic patients compared with healthy controls. Eur. J. Gastroenterol. Hepatol. 2012; 24(10): 1158–65. DOI: 10.1097/MEG.0b013e328355cfd0Suzuki Y., Saito H., Suzuki M. et al. Up-regulation of transferrin receptor expression in hepatocytes by habitual alcohol drinking is implicated in hepatic iron overload in alcoholic liver disease. Alcohol. Clin. Exp. Res. 2002; 26(suppl.8): S26–31. DOI: 10.1097/01.ALC.0000026830.27338.23Suzuki Y., Saito H., Suzuki M. et al. Up-regulation of transferrin receptor expression in hepatocytes by habitual alcohol drinking is implicated in hepatic iron overload in alcoholic liver disease. Alcohol. Clin. Exp. Res. 2002; 26(suppl.8): S26–31. DOI: 10.1097/01.ALC.0000026830.27338.23Harrison-Findik D.D., Schafer D., Klein E. et al. Alcohol metabolism mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J. Biol. Chem. 2006; 281(32): 22974–82. DOI: 10.1074/jbc.M602098200Harrison-Findik D.D., Schafer D., Klein E. et al. Alcohol metabolism mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J. Biol. Chem. 2006; 281(32): 22974–82. DOI: 10.1074/jbc.M602098200Gerjevic L.N., Liu N., Lu S. et al. Alcohol activates TGF-beta but inhibits BMP receptor-mediated Smad signaling and Smad4 binding to hepcidin promoter in the liver. Int. J. Hepatol. 2012; 2012: 459278. DOI: 10.1155/2012/459278Gerjevic L.N., Liu N., Lu S. et al. Alcohol activates TGF-beta but inhibits BMP receptor-mediated Smad signaling and Smad4 binding to hepcidin promoter in the liver. Int. J. Hepatol. 2012; 2012: 459278. DOI: 10.1155/2012/459278Xiong S., She H., Zhang A.S. et al. Hepatic macrophage iron aggravates experimental alcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2008; 295(3): 512–21. DOI: 10.1152/ajpgi.90327.2008Xiong S., She H., Zhang A.S. et al. Hepatic macrophage iron aggravates experimental alcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2008; 295(3): 512–21. DOI: 10.1152/ajpgi.90327.2008Kowdley K.V. Iron overload in patients with chronic liver disease. Gastroenterol. Hepatol. (N Y). 2016; 12(11): 695–8.Kowdley K.V. Iron overload in patients with chronic liver disease. Gastroenterol. Hepatol. (N Y). 2016; 12(11): 695–8.Chirumbolo S., Rossi A.P., Rizzatti V. et al. Iron primes 3T3-L1 adipocytes to a TLR4-mediated inflammatory response. Nutrition. 2015; 31(10): 1266–74. DOI: 10.1016/j.nut.2015.04.007Chirumbolo S., Rossi A.P., Rizzatti V. et al. Iron primes 3T3-L1 adipocytes to a TLR4-mediated inflammatory response. Nutrition. 2015; 31(10): 1266–74. DOI: 10.1016/j.nut.2015.04.007Datz C., Müller E., Aigner E. Iron overload and non-alcoholic fatty liver disease. Minerva Endocrinol. 2017; 42(2): 173–83. DOI: 10.23736/S0391-1977.16.02565-7Datz C., Müller E., Aigner E. Iron overload and non-alcoholic fatty liver disease. Minerva Endocrinol. 2017; 42(2): 173–83. DOI: 10.23736/S0391-1977.16.02565-7Kowdley K.V., Belt P., Wilson L.A. et al.; NASH Clinical Research Network. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012; 55(1): 77–85. DOI: 10.1002/hep.24706Kowdley K.V., Belt P., Wilson L.A. et al.; NASH Clinical Research Network. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012; 55(1): 77–85. DOI: 10.1002/hep.24706Britton L.J., Subramaniam V.N., Crawford D.H. Iron and non alcoholic fatty liver disease. World J. Gastroenterol. 2016; 22(36): 8112–22. DOI: 10.3748/wjg.v22.i36.8112Britton L.J., Subramaniam V.N., Crawford D.H. Iron and non alcoholic fatty liver disease. World J. Gastroenterol. 2016; 22(36): 8112–22. DOI: 10.3748/wjg.v22.i36.8112Kim C.W., Chang Y., Sung E. et al. Serum ferritin levels predict incident non-alcoholic fatty liver disease in healthy Korean men. Metabolism. 2012; 61(8): 1182–8. DOI: 10.1016/j.metabol.2012.01.007Kim C.W., Chang Y., Sung E. et al. Serum ferritin levels predict incident non-alcoholic fatty liver disease in healthy Korean men. Metabolism. 2012; 61(8): 1182–8. DOI: 10.1016/j.metabol.2012.01.007Dongiovanni P., Fracanzani A.L., Fargion S. et al. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J. Hepatol. 2011; 55(4): 920–32. DOI: 10.1016/j.jhep.2011.05.008Dongiovanni P., Fracanzani A.L., Fargion S. et al. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J. Hepatol. 2011; 55(4): 920–32. DOI: 10.1016/j.jhep.2011.05.008Gabrielsen J.S., Gao Y., Simcox J.A. et al. Adipocyte iron regulates adiponectin and insulin sensitivity. J. Clin. Invest. 2012; 122(10): 3529–40. DOI: 10.1172/JCI44421Gabrielsen J.S., Gao Y., Simcox J.A. et al. Adipocyte iron regulates adiponectin and insulin sensitivity. J. Clin. Invest. 2012; 122(10): 3529–40. DOI: 10.1172/JCI44421Pihan-Le Bars F., Bonnet F., Loréal O. et al. Indicators of iron status are correlated with adiponectin expression in adipose tissue of patients with morbid obesity. Diabetes Metab. 2016; 42(2): 105– 11. DOI: 10.1016/j.diabet.2015.10.007Pihan-Le Bars F., Bonnet F., Loréal O. et al. Indicators of iron status are correlated with adiponectin expression in adipose tissue of patients with morbid obesity. Diabetes Metab. 2016; 42(2): 105– 11. DOI: 10.1016/j.diabet.2015.10.007Fernández-Real J.M., Peñarroja G., Castro A. et al. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes. 2002; 51(4): 1000–4. DOI: 10.2337/diabetes.51.4.1000Fernández-Real J.M., Peñarroja G., Castro A. et al. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes. 2002; 51(4): 1000–4. DOI: 10.2337/diabetes.51.4.1000Houschyar K.S., Lüdtke R., Dobos G.J. et al. Effects of phlebotomy induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial. BMC Med. 2012; 10: 54. DOI: 10.1186/1741-7015-10-54Houschyar K.S., Lüdtke R., Dobos G.J. et al. Effects of phlebotomy induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial. BMC Med. 2012; 10: 54. DOI: 10.1186/1741-7015-10-54Adams L.A., Crawford D.H., Stuart K. et al. The impact of phlebotomy in nonalcoholic fatty liver disease: a prospective, randomized, controlled trial. Hepatology. 2015; 61(5): 1555–64. DOI: 10.1002/hep.27662Adams L.A., Crawford D.H., Stuart K. et al. The impact of phlebotomy in nonalcoholic fatty liver disease: a prospective, randomized, controlled trial. Hepatology. 2015; 61(5): 1555–64. DOI: 10.1002/hep.27662Nelson J.E., Wilson L., Brunt E.M. et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology. 2011; 53(2): 448–57. DOI: 10.1002/hep.24038Nelson J.E., Wilson L., Brunt E.M. et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology. 2011; 53(2): 448–57. DOI: 10.1002/hep.24038Eder S.K., Feldman A., Strebinger G. et al. Mesenchymal iron deposition is associated with adverse long-term outcome in non alcoholic fatty liver disease. Liver Int. 2020; 40(8): 1872–82. DOI: 10.1111/liv.14503Eder S.K., Feldman A., Strebinger G. et al. Mesenchymal iron deposition is associated with adverse long-term outcome in non alcoholic fatty liver disease. Liver Int. 2020; 40(8): 1872–82. DOI: 10.1111/liv.14503

The authors declare that there are no conflicts of interest present.